Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Mark L Tykocinski"'
Autor:
Alexandra Aronin, Shira Amsili, Tatyana B Prigozhina, Kobi Tzdaka, Jacob Rachmilewitz, Noam Shani, Mark L Tykocinski, Michal Dranitzki Elhalel
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e77050 (2013)
BACKGROUND:New strategies for the treatment of hepatocellular carcinoma (HCC) are needed, given that currently available chemotherapeutics are inefficient. Since tumor growth reflects the net balance between pro-proliferative and death signaling, age
Externí odkaz:
https://doaj.org/article/2abdbdcf2b784c789083154a29afa674
Autor:
Zohar Ochanuna, Anat Geiger-Maor, Adi Dembinsky-Vaknin, Dimitrios Karussis, Mark L Tykocinski, Jacob Rachmilewitz
Publikováno v:
PLoS ONE, Vol 5, Iss 9, p e12868 (2010)
T-helper polarization of naïve T cells is determined by a complex mechanism that involves many factors, eventually leading to activation of Th1, Th2, or Th17 responses or alternatively the generation of regulatory T cells. Placental Protein 14 (PP14
Externí odkaz:
https://doaj.org/article/a7ca9747ff114a21af3bc3592e12fc6f
Autor:
Michal Dranitzki Elhalel, Mark L. Tykocinski, Noam Shani, Fanny Shkedy, Jitka Yehudith Sagiv, Liat Ben Gigi–Tamir, Yosi Meir Gozlan, Kobi Tzdaka, Tatyana B. Prigozhina, Alexandra Aronin, Shira Amsili, Efi Makdasi
Cytotoxic T-lymphocyte antigen 4 (CTLA4)-FasL, a homo-hexameric signal converter protein, is capable of inducing robust apoptosis in malignant cells of the B-cell lineage expressing its cognate B7 and Fas targets, while sparing nonmalignant ones. Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8acdcf063baf664e37a78b4888b1cb1
https://doi.org/10.1158/1535-7163.c.6542272.v1
https://doi.org/10.1158/1535-7163.c.6542272.v1
Autor:
Michal Dranitzki Elhalel, Mark L. Tykocinski, Noam Shani, Fanny Shkedy, Jitka Yehudith Sagiv, Liat Ben Gigi–Tamir, Yosi Meir Gozlan, Kobi Tzdaka, Tatyana B. Prigozhina, Alexandra Aronin, Shira Amsili, Efi Makdasi
(a) Receptors expression on human cell lines and mouse BCL-1 splenocytes. (b) Anti CTLA4-FasL antibodies are formed in treated mice. (c) Neutralizing anti CTLA4-FasL antibodies are formed in treated mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b964846c2e67de8d26eac159f86a21bb
https://doi.org/10.1158/1535-7163.22519081.v1
https://doi.org/10.1158/1535-7163.22519081.v1
Autor:
Jonathan R. Brody, Mark L. Tykocinski, Rajanikanth Vadigepalli, Charles J. Yeo, Nicole Meisner-Kober, Jonathan N. Sachs, Janet A. Sawicki, Jordan M. Winter, Angie D. Lobo, Saswati N. Chand, Danielle DeCicco, Mahsa Zarei, Matthew C. Weber, Carmella Romeo
Supplemental Figure Images
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d0eb329b7ad88b1e22c594b46622ee1
https://doi.org/10.1158/1541-7786.22511716
https://doi.org/10.1158/1541-7786.22511716
Autor:
Jonathan R. Brody, Mark L. Tykocinski, Rajanikanth Vadigepalli, Charles J. Yeo, Nicole Meisner-Kober, Jonathan N. Sachs, Janet A. Sawicki, Jordan M. Winter, Angie D. Lobo, Saswati N. Chand, Danielle DeCicco, Mahsa Zarei, Matthew C. Weber, Carmella Romeo
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal cancers, in part, due to resistance to both conventional and targeted therapeutics. TRAIL directly induces apoptosis through engagement of cell surface Death Receptors (DR4 and DR5), an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34413c451ad46f9bdc5d759366dc3e0d
https://doi.org/10.1158/1541-7786.c.6540022.v1
https://doi.org/10.1158/1541-7786.c.6540022.v1
Autor:
Michal Dranitzki Elhalel, Mark L. Tykocinski, Noam Shani, Fanny Shkedy, Jitka Yehudith Sagiv, Liat Ben Gigi–Tamir, Yosi Meir Gozlan, Kobi Tzdaka, Tatyana B. Prigozhina, Alexandra Aronin, Shira Amsili, Efi Makdasi
Table S1. Summary of the Toxicokinetic Parameters of CTLA4-FasL in mouse Plasma at the first injection (Day 1) and the third injection (Day 5) Table S2. Summary of the Pharmacokinetic parameters in a single dose of CTLA4-FasL in Cynomolgus monkey pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68c90efa3cfd76a11505c99d79171c4e
https://doi.org/10.1158/1535-7163.22519057.v1
https://doi.org/10.1158/1535-7163.22519057.v1
Autor:
Michal Dranitzki Elhalel, Mark L. Tykocinski, Noam Shani, Fanny Shkedy, Jitka Yehudith Sagiv, Liat Ben Gigi–Tamir, Yosi Meir Gozlan, Kobi Tzdaka, Tatyana B. Prigozhina, Alexandra Aronin, Shira Amsili, Efi Makdasi
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1700b3bdd4de82a3cc3d1d6b0fa0dc1e
https://doi.org/10.1158/1535-7163.22519060.v1
https://doi.org/10.1158/1535-7163.22519060.v1
Autor:
Jonathan R. Brody, Mark L. Tykocinski, Rajanikanth Vadigepalli, Charles J. Yeo, Nicole Meisner-Kober, Jonathan N. Sachs, Janet A. Sawicki, Jordan M. Winter, Angie D. Lobo, Saswati N. Chand, Danielle DeCicco, Mahsa Zarei, Matthew C. Weber, Carmella Romeo
Supplemental Figure Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bd335ede44214512d502d655f8c375f
https://doi.org/10.1158/1541-7786.22511713
https://doi.org/10.1158/1541-7786.22511713
Autor:
Matthew P. Weber, Elina Zorde-Khvalevsky, Amnon Peled, Adam Foley-Comer, Ami Tamir, Ayelet Chajut, Lucy Ganthous, Alexandra Aronin, Rinat Tabakman, Shirley Greenwald, Jasmine Avichzer, Roy Kahn, Mark L. Tykocinski, Iris Pecker, Liat Ben Gigi Tamir, Michal Michal Elhalel Dranitzki
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundTIGIT, an inhibitory immune checkpoint, is a target of interest for immuno-oncology combination therapies. TIGIT is part of a complex molecular network containing four receptors (DNAM1, TIGIT, PVRIG and CD96) and two ligands (PVR and PVRL2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ace81f6d30f90242de6e37a20b6a0608
https://doaj.org/article/9d1d813fb3514e5b91af359675727c2a
https://doaj.org/article/9d1d813fb3514e5b91af359675727c2a